Literature DB >> 34694420

Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan.

Ryoko Kimura1, Kazunari Sugita, Takaaki Sugihara, Hajime Isomoto, Osamu Yamamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34694420      PMCID： PMC9455316          DOI： 10.2340/actadv.v101.439

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  16 in total

1.  Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.

Authors:  Tatyana Zvyaga; Shu-Ying Chang; Cliff Chen; Zheng Yang; Ragini Vuppugalla; Jeremy Hurley; Denise Thorndike; Andrew Wagner; Anjaneya Chimalakonda; A David Rodrigues
Journal:  Drug Metab Dispos       Date:  2012-05-30       Impact factor: 3.922

Review 2.  Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

Authors:  Takahisa Furuta; Naohito Shirai; Mitsushige Sugimoto; Akiko Nakamura; Akira Hishida; Takashi Ishizaki
Journal:  Drug Metab Pharmacokinet       Date:  2005-06       Impact factor: 3.614

Review 3.  Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future.

Authors:  Lászlo Herszényi; Tamás Bakucz; Loránd Barabás; Zsolt Tulassay
Journal:  Dig Dis       Date:  2019-12-17       Impact factor: 2.404

4.  The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.

Authors:  Carmelo Scarpignato; Richard H Hunt
Journal:  Curr Opin Gastroenterol       Date:  2019-07       Impact factor: 3.287

5.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

Authors:  Xue-Qing Li; Tommy B Andersson; Marie Ahlström; Lars Weidolf
Journal:  Drug Metab Dispos       Date:  2004-08       Impact factor: 3.922

6.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

Authors:  G Danan; C Benichou
Journal:  J Clin Epidemiol       Date:  1993-11       Impact factor: 6.437

Review 7.  The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

8.  Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis.

Authors:  Theresa Tingey; Jenny Shu; Joseph Smuczek; Janet Pope
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-09       Impact factor: 4.794

Review 9.  Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters.

Authors:  Nuggehally R Srinivas
Journal:  Gen Physiol Biophys       Date:  2016-04-05       Impact factor: 1.512

10.  Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo.

Authors:  Yiran Wang; Changxiong Wang; Shuanghu Wang; Quan Zhou; Dapeng Dai; Jihua Shi; Xue Xu; Qingfeng Luo
Journal:  Front Pharmacol       Date:  2020-02-14       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.